Novartis AG sells Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets under Brand name Zortress in the USA market.
Drug maker Natco Pharma Ltd Friday said its marketing partner in the US Breckenridge Pharmaceutical Inc (BPI) has filed an Abbreviated New Drug Application (ANDA) for Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets.
"Natco and BPI believe that its Paragraph IV ANDA was filed on the First-to-File date and expects to be the only generic that is entitled to the 180-day exclusivity period," city-based Natco said in a filing with bourses.
Novartis AG sells Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets under Brand name Zortress in the USA market.
The drug which is used to prevent organ rejection after a kidney or liver transplant, generated sales of USD 43.5 million for the twelve-month period ending July 2014, based on industry sales data, Natco said.
Shares of Natco today closed higher by 5 percent at Rs 1,438.60 on the BSE.
Natco Pharma stock price
On August 22, 2014, Natco Pharma closed at Rs 1438.60, up Rs 68.50, or 5.00 percent. The 52-week high of the share was Rs 1438.60 and the 52-week low was Rs 585.00.
The company's trailing 12-month (TTM) EPS was at Rs 36.90 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 38.99. The latest book value of the company is Rs 160.81 per share. At current value, the price-to-book value of the company is 8.95.
Anda sedang membaca artikel tentang
Natco pharma's US partner files ANDA for Everolimus
Dengan url
http://kebugaranhidup.blogspot.com/2014/09/natco-pharmas-us-partner-files-anda-for.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Natco pharma's US partner files ANDA for Everolimus
namun jangan lupa untuk meletakkan link
Natco pharma's US partner files ANDA for Everolimus
sebagai sumbernya
0 komentar:
Posting Komentar